TokenPost·
Amgen Announces Positive Phase 3 Results for Sjögren’s Drug
The results came from the OASIZ-301 study of dazodalibep. Amgen plans to present the full findings at ACR Convergence 2026.
More news
- TokenPostPlurai Raises $13 Million to Simulate Enterprise AI Agent Tasks
- TokenPostUnity and Nvidia’s NVentures Join Emulate’s $700 Million Round
- TokenPostCathay Group Orders 14 Airbus Jets for Cathay Pacific and HK Express
- TokenPostOKXICE Sets Nov. 23 Launch; 67 Issuers Objected by Nov. 5
- Crypto BriefingNvidia reportedly taps outside firm to scout potential CEO candidates
- Bitcoin.com NewsPolymarket Trims Staff and Contractors as It Eyes Going Public: Report